- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01558856
Unilateral Versus Bilateral Neuromodulation Tests in the Treatment of Refractory Idiopathic Overactive Bladder (HAVIR Bi)
August 3, 2020 updated by: Centre Hospitalier Universitaire de Nīmes
Prospective Randomized Trial Comparing Unilateral and Bilateral Neuromodulation Tests in the Treatment of Refractory Idiopathic Overactive Bladder
The primary objective of this study is to compare the efficacy of unilateral and bilateral neuromodulation tests at 1 month.
Study Overview
Status
Completed
Conditions
Detailed Description
The secondary objectives of this study are to compare the following elements between a group of patients undergoing unilater modulation tests (standard procedure) and a group of patients undergoing bilateral neuromodulation tests (experimental procedure) (at 1 month): Pollakiuria, pad use, urge incontinence, symptom severity, % of patients not eligible for an implant, debimetry, tolerance, complications, quality of life.
Study Type
Interventional
Enrollment (Actual)
55
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Montpellier, France, 34070
- Clinique Beau Soleil
-
Nantes Cedex 1, France, 44093
- CHU de Nantes - Hotel Dieu
-
Nîmes Cedex 09, France, 30029
- CHU de Nîmes - Hôpital Universitaire Carémeau
-
Paris Cedex 13, France, 75651
- APHP - Groupe Hospitalier Pitié-Salpetrière
-
Rouen, France, 76031
- CHU de Rouen - Hopital Charles Nicolle
-
Toulouse Cedex 9, France, 31059
- CHRU de Toulouse - Hôpital de Rangueil
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- The patient must have given his/her informed and signed consent
- The patient must be insured or beneficiary of a health insurance plan
- The patient is available for 1 month of follow-up
- The patient understands and reads French
- The patient has symptoms of overactive bladder resistant to first-line treatments (physiotherapy, anticholinergics)
- The patient suffers from an overactive bladder confirmed by a urodynamic panel
- The patient suffers from an overactive bladder unassociated with bladder obstruction as confirmed by flowmetry
- The patient has primary (idiopathic) overactive bladder primary with normal urinalysis, abdominal and pelvic ultrasound, urine cytology + / - cystoscopy
- The patient has no bleeding disorders, or the disorder is properly controlled after treatment
Exclusion Criteria:
- The patient is participating in another study
- The patient is in an exclusion period determined by a previous study
- The patient is under judicial protection, under tutorship or curatorship
- The patient refuses to sign the consent
- It is impossible to correctly inform the patient
- The patient is pregnant, parturient, or breastfeeding
- Overactive bladder associated with bladder obstruction as determined by flowmetry
- Overactive bladder unconfirmed by urodynamic panel
- Overactive bladder secondary to another condition:
- vesical: urolithiasis, bladder polyp, interstitial cystitis
- pelivienne: tumor or inflammatory
- neurological: multiple sclerosis, brain tumor, epilepsy
- the patient has an uncorrectable bleeding disorder
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Unilateral testing
Following standard procedures, patients in this group will have unilateral testing for neuromodulation of the sacral nerves. Intervention: Unilateral electrode placement and testing |
An electrode is placed near a sacral nerve with an anal motor response under general anesthesia.
During and adjustment phase, the electode is connected to a test box which allows for adjustment of stimulation parameters.
After pinpointing stimulation parameters, the external test box is replaced by an implanted device.
|
EXPERIMENTAL: Bilateral testing
Patients in this group will have bilateral testing for neuromodulation of the sacral nerves. Intervention: Bilateral electrode placement and testing |
Two electrodes are placed, one near each sacral nerve under general anesthesia.
During an adjustment phase, the electodes are connected to a test box which allows for adjustment of stimulation parameters.
This can result in the use of one or the other, or both electrodes, thus increasing the chances of success and the possibility that the patient is eligible for an implant.
After pinpointing stimulation parameters, the external test box is replaced by an implanted device.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Success rate
Time Frame: 1 month
|
"Success" is defined as a >= 50% improvement in at least one of the following symtoms: pollakiuria, number of urge incontinence episodes with incontinence, number of urge incontinence episodes.
|
1 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
presence/absence: 50% reduction in the number of daily mictions
Time Frame: 1 month
|
1 month
|
|
presence/absence: 50% reduction in the number of pads/protections used per day
Time Frame: 1 month
|
1 month
|
|
presence/absence: 50% reduction in the number of urge incontinence episodes per day
Time Frame: 1 month
|
1 month
|
|
presence/absence: 50% reduction in the number of urge incontinence episodes with incontinence per day
Time Frame: 1 month
|
1 month
|
|
Symptom severity as measured by the MHU score
Time Frame: 1 month
|
MHU = Mesure Hanicap Urinaire
|
1 month
|
Yes/no: the patient was eligible for an implant
Time Frame: 1 month
|
1 month
|
|
debimetry: flow rate per voiding
Time Frame: 1 month
|
1 month
|
|
debimetry: urinary volume per voiding
Time Frame: 1 month
|
1 month
|
|
Visual analog scale for pain at the implantation site
Time Frame: 1 month
|
1 month
|
|
Visual analog scale for pain due to neuro stimulation (pain in legs or buttocks)
Time Frame: 1 month
|
1 month
|
|
Presence/absence of infection of the implant or electrode
Time Frame: 1 month
|
1 month
|
|
Change in quality of life: IQoL score
Time Frame: baseline to 1 month
|
baseline to 1 month
|
|
Change in quality of life: KHQ score
Time Frame: baseline to 1 month
|
baseline to 1 month
|
|
Change in quality of life: SF 36 score
Time Frame: baseline to 1 month
|
baseline to 1 month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Laurent Wagner, MD, Centre Hospitalier Universitaire de Nîmes
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
October 23, 2012
Primary Completion (ACTUAL)
September 20, 2017
Study Completion (ACTUAL)
January 23, 2018
Study Registration Dates
First Submitted
March 18, 2012
First Submitted That Met QC Criteria
March 18, 2012
First Posted (ESTIMATE)
March 20, 2012
Study Record Updates
Last Update Posted (ACTUAL)
August 5, 2020
Last Update Submitted That Met QC Criteria
August 3, 2020
Last Verified
August 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LOCAL/2011/LW-04
- 2012-A00185-38 (OTHER: RCB number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Urinary Bladder, Overactive
-
Merck Sharp & Dohme LLCTerminatedOveractive Bladder | Overactive Urinary Bladder
-
Ankara Yildirim Beyazıt UniversityCompletedOveractive Bladder | Overactive Detrusor | Overactive Bladder SyndromeTurkey
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedOveractive Bladder (OAB)United States, Canada, Germany, Korea, Republic of, Spain, Turkey, Taiwan, Italy, Slovakia, Denmark, South Africa, United Kingdom, Mexico, Sweden, Norway
-
Medstar Health Research InstituteColumbia University; University of Michigan; University of New Mexico; Methodist...Terminated
-
Astellas Pharma Global Development, Inc.CompletedOveractive Bladder (OAB)United States, Canada
-
Loyola UniversityAstellas Pharma IncCompletedOveractive Bladder SyndromeUnited States
-
Beijing Pins Medical Co., LtdUnknown
-
Maastricht University Medical CenterUnknownLower Urinary Tract Symptoms | Overactive Bladder SyndromeNetherlands
-
Pamukkale UniversityCompletedElectrical Stimulation | Idiopathic Overactive Bladder | Bladder TrainingTurkey
Clinical Trials on Unilateral electrode placement and testing
-
China-Japan Friendship HospitalUnknownMechanical Complication of Cardiac PacemakerChina
-
Northwell HealthEnrolling by invitationEpilepsyUnited States
-
Scientific Institute San RaffaeleRecruiting
-
VA Office of Research and DevelopmentRecruitingDiabetic Peripheral Neuropathy | Lower Extremity AmputeeUnited States
-
NYU Langone HealthCompleted
-
Changi General HospitalSingapore General HospitalRecruitingPrimary Aldosteronism | Hypokalemia | Chronic Renal Disease | Cardiovascular Morbidity | Mineralocorticoid Excess | Adrenalectomy; Status | Primary Aldosteronism Due to Aldosterone Producing Adenoma | Primary Aldosteronism Due to Adrenal Hyperplasia (Bilateral) | Mineralocorticoid Antagonists [Aldosterone...Singapore
-
Zagazig UniversityNot yet recruitingInguinal Hernia,Quadratus Lumborum Block , Unilateral Intrathecal Block
-
National Taiwan University Hospital Hsin-Chu BranchRecruiting
-
Yariv yogevOB-Tools Ltd.Unknown
-
Erasmus Medical CenterCompletedStrabismusNetherlands, Germany